Insider Buying: Korro Bio (NASDAQ:KRRO) Major Shareholder Acquires $2,300,881.00 in Stock

Korro Bio, Inc. (NASDAQ:KRRO) major shareholder Forest Baskett purchased 207,100 shares of the stock in a transaction that occurred on Tuesday, March 10th. The stock was purchased at an average cost of $11.11 per share, with a total value of $2,300,881.00. Following the purchase, the insider owned 1,297,893 shares in the company, valued at $14,419,591.23. This represents a 18.99% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Korro Bio Stock Performance

Shares of KRRO opened at $12.80 on Friday. The firm has a market cap of $120.58 million, a PE ratio of -1.03 and a beta of 2.98. The firm’s 50 day moving average price is $10.99 and its 200 day moving average price is $20.18. Korro Bio, Inc. has a twelve month low of $5.20 and a twelve month high of $55.89.

Korro Bio (NASDAQ:KRRO) last posted its earnings results on Thursday, March 12th. The company reported ($5.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.93) by ($3.39). The business had revenue of $1.29 million during the quarter, compared to analyst estimates of $0.43 million. Korro Bio had a negative net margin of 1,834.48% and a negative return on equity of 99.63%. On average, sell-side analysts anticipate that Korro Bio, Inc. will post -9.52 earnings per share for the current fiscal year.

Trending Headlines about Korro Bio

Here are the key news stories impacting Korro Bio this week:

• Positive Sentiment: Raymond James upgraded KRRO from “market perform” to “outperform” and set a $23 price target, providing a prominent analyst endorsement that can attract momentum and institutional buyers. Read More.
• Positive Sentiment: Multiple major shareholders and investors (including Enterprise Associates/NEA‑17, Forest Baskett, Scott Sandell and others) disclosed large purchases (~207,100 shares at ~$11.11 each), signaling strong insider/large‑holder conviction and providing buying support. Read More.
• Positive Sentiment: Corporate update: Korro nominated KRRO‑121 for hyperammonemia, is advancing a GalNAc oligo candidate for AAT deficiency (on track to nominate in Q2 2026), and closed an oversubscribed $85M private placement, which management says extends cash runway into H2 2028 — materially reducing near‑term financing risk. Read More.
• Neutral Sentiment: Revenue for Q4 modestly exceeded expectations ($1.29M vs. ~ $0.42M est.), but the amount is very small relative to R&D and operating burn, so near‑term profit improvement is limited. Read More.
• Negative Sentiment: Quarterly and annual results show heavy write‑downs and operating losses: Q4 EPS was a ($5.32) miss vs. consensus (~($1.93)), and full‑year net loss widened (reported ~$117.3M) driven by non‑cash impairment charges — highlighting high execution risk and potential for volatility if clinical progress stalls. Read More. Read More.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on KRRO. Chardan Capital upgraded shares of Korro Bio from a “neutral” rating to a “buy” rating and set a $15.00 price objective for the company in a report on Thursday, January 29th. Raymond James Financial upgraded Korro Bio from a “market perform” rating to an “outperform” rating and set a $23.00 target price on the stock in a report on Friday. Clear Str raised Korro Bio from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 18th. Wall Street Zen downgraded Korro Bio from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Korro Bio in a report on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Korro Bio has an average rating of “Moderate Buy” and an average target price of $44.50.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. bought a new position in Korro Bio in the 3rd quarter worth $39,000. Wells Fargo & Company MN boosted its holdings in Korro Bio by 45.5% during the fourth quarter. Wells Fargo & Company MN now owns 7,522 shares of the company’s stock valued at $60,000 after acquiring an additional 2,352 shares during the period. Guggenheim Capital LLC bought a new stake in Korro Bio during the fourth quarter valued at about $84,000. Jain Global LLC acquired a new stake in shares of Korro Bio in the fourth quarter valued at about $85,000. Finally, Deutsche Bank AG grew its position in shares of Korro Bio by 241.9% in the fourth quarter. Deutsche Bank AG now owns 12,758 shares of the company’s stock valued at $102,000 after purchasing an additional 9,027 shares during the last quarter. 13.18% of the stock is currently owned by institutional investors and hedge funds.

About Korro Bio

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.